Laropiprant (BioDeep_00000600811)
代谢物信息卡片
4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-cyclopent[b]indole-3-acetic acid
化学式: C21H19ClFNO4S (435.0707296000001)
中文名称: 拉罗皮兰
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F
InChI: InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
描述信息
C177182 - Prostaglandin Receptor Antagonist
C26170 - Protective Agent
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:135942
- KEGGdrug: D08940
- PubChem: 9867642
- Metlin: METLIN45200
- DrugBank: DB11629
- ChEMBL: CHEMBL426559
- CAS: 571170-77-9
- CAS: 572874-50-1
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Wataru Suto, Yusuke Ando, Takahiro Hirabayashi, Fumiko Takenoya, Seiji Shioda, Junzo Kamei, Hiroyasu Sakai, Yoshihiko Chiba. Prostaglandin D₂ Induces Ca2+ Sensitization of Contraction without Affecting Cytosolic Ca2+ Level in Bronchial Smooth Muscle.
International journal of molecular sciences.
2018 Oct; 19(10):. doi:
10.3390/ijms19103036. [PMID: 30301147] - Sarah Parish, Jemma C Hopewell, Michael R Hill, Santica Marcovina, Elsa Valdes-Marquez, Richard Haynes, Alison Offer, Terje R Pedersen, Colin Baigent, Rory Collins, Martin Landray, Jane Armitage. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.
Circulation. Genomic and precision medicine.
2018 02; 11(2):e001696. doi:
10.1161/circgen.117.001696. [PMID: 29449329] - Eliot A Brinton, Joseph Triscari, Philippe Brudi, Erluo Chen, Amy O Johnson-Levonas, Christine McCrary Sisk, Rae Ann Ruck, Alexandra A MacLean, Darbie Maccubbin, Yale B Mitchel. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
Lipids in health and disease.
2016 Jul; 15(1):116. doi:
10.1186/s12944-016-0282-8. [PMID: 27405296] - Gabriele Cioni, Lucia Mannini, Alessandrello Agatina Liotta, Giovanna D'Alessandri, Cinzia Fatini, Brunella Bandinelli, Maria Costanzo, Rosanna Abbate, Rossella Marcucci. Detrimental effects of niacin/laropiprant on microvascular reactivity and red cell deformability in patients with elevated lipoprotein(a) levels.
Journal of thrombosis and thrombolysis.
2016 Apr; 41(3):433-5. doi:
10.1007/s11239-015-1256-9. [PMID: 26289089] - Petra El Khoury, Elisa Waldmann, Thierry Huby, Julie Gall, Philippe Couvert, Jean-Marc Lacorte, John Chapman, Eric Frisdal, Philippe Lesnik, Klaus G Parhofer, Wilfried Le Goff, Maryse Guerin. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.
Arteriosclerosis, thrombosis, and vascular biology.
2016 Feb; 36(2):285-94. doi:
10.1161/atvbaha.115.306834. [PMID: 26681758] - Núria Amigó, Roger Mallol, Mercedes Heras, Sergio Martínez-Hervás, Francisco Blanco Vaca, Joan Carles Escolà-Gil, Núria Plana, Óscar Yanes, Lluís Masana, Xavier Correig. Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: 'Herniated' HDL, a common feature in diabetes.
Scientific reports.
2016 Jan; 6(?):19249. doi:
10.1038/srep19249. [PMID: 26778677] - Christopher Labos, James M Brophy, George Thanassoulis. Placing HPS2-THRIVE in context using Bayesian analysis.
International journal of cardiology.
2015 Sep; 195(?):203-4. doi:
10.1016/j.ijcard.2015.05.156. [PMID: 26048375] - Rahul Yadav, Yifen Liu, See Kwok, Salam Hama, Michael France, Ruth Eatough, Phil Pemberton, Jonathan Schofield, Tarza J Siahmansur, Rayaz Malik, Basil A Ammori, Basil Issa, Naveed Younis, Rachelle Donn, Adam Stevens, Paul Durrington, Handrean Soran. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
Journal of the American Heart Association.
2015 Sep; 4(9):e001508. doi:
10.1161/jaha.114.001508. [PMID: 26374297] - Brett Lauring, Victor Dishy, Pieter-Jan De Kam, Tami Crumley, Larissa Wenning, Fang Liu, Christine Sisk, John Wagner, Eseng Lai. Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects.
American journal of therapeutics.
2015 Sep; 22(5):367-76. doi:
10.1097/mjt.0000000000000051. [PMID: 24832384] - Luís Masana, Anna Cabré, Mercedes Heras, Núria Amigó, Xavier Correig, Sergio Martínez-Hervás, José T Real, Juan F Ascaso, Helena Quesada, Josep Julve, Xavier Palomer, Manuel Vázquez-Carrera, Josefa Girona, Núria Plana, Francisco Blanco-Vaca. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Atherosclerosis.
2015 Feb; 238(2):213-9. doi:
10.1016/j.atherosclerosis.2014.12.006. [PMID: 25528430] - Miao Hu, Ya-Ling Yang, Daisaku Masuda, Shizuya Yamashita, Brian Tomlinson. Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia.
Disease markers.
2015; 2015(?):154014. doi:
10.1155/2015/154014. [PMID: 26063948] - Harold E Bays, Eliot A Brinton, Joseph Triscari, Erluo Chen, Darbie Maccubbin, Alexandra A MacLean, Kendra L Gibson, Rae Ann Ruck, Amy O Johnson-Levonas, Edward A O'Neill, Yale B Mitchel. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
Vascular health and risk management.
2015; 11(?):165-72. doi:
10.2147/vhrm.s70907. [PMID: 25750540] - Anastazia Kei, Constantinos Tellis, Evangelos Liberopoulos, Alexandros Tselepis, Moses Elisaf. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Cardiovascular therapeutics.
2014 Aug; 32(4):139-46. doi:
10.1111/1755-5922.12072. [PMID: 24618208] - M M Aye, E S Kilpatrick, P Afolabi, S A Wootton, A S Rigby, A M Coady, D D Sandeman, S L Atkin. Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
Diabetes, obesity & metabolism.
2014 Jun; 16(6):545-52. doi:
10.1111/dom.12255. [PMID: 24401089] - Valeria Nasser Figueiredo, Felipe Vendrame, Bruno A Colontoni, Thiago Quinaglia, Jose Roberto Matos-Souza, Filipe Azevedo Moura, Otavio R Coelho, Eliana C de Faria, Andrei C Sposito. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial.
Clinical therapeutics.
2014 Jun; 36(6):961-6. doi:
10.1016/j.clinthera.2014.03.012. [PMID: 24768191] - Urska Bregar, Borut Jug, Irena Keber, Matija Cevc, Miran Sebestjen. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction.
Heart and vessels.
2014 May; 29(3):313-9. doi:
10.1007/s00380-013-0367-5. [PMID: 23712600] - Ana Cenarro, José Puzo, Juan Ferrando, Rocío Mateo-Gallego, Ana M Bea, Pilar Calmarza, Estíbaliz Jarauta, Fernando Civeira. Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype.
Metabolism: clinical and experimental.
2014 Mar; 63(3):365-71. doi:
10.1016/j.metabol.2013.10.014. [PMID: 24333007] - Michel Farnier, Erluo Chen, Amy O Johnson-Levonas, Christine McCrary Sisk, Yale B Mitchel. Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Vascular health and risk management.
2014; 10(?):279-90. doi:
10.2147/vhrm.s58694. [PMID: 24855368] - Pieter-Jan De Kam, Wen-Lin Luo, Larissa Wenning, Lisa Ratcliffe, Christine McCrary Sisk, Jane Royalty, Waldemar Radziszewski, John A Wagner, Eseng Lai. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
Platelets.
2014; 25(7):480-7. doi:
10.3109/09537104.2013.836747. [PMID: 24206527] - Madhumathi Rao, Michael Steffes, Andrew Bostom, Joachim H Ix. Effect of niacin on FGF23 concentration in chronic kidney disease.
American journal of nephrology.
2014; 39(6):484-90. doi:
10.1159/000362424. [PMID: 24854458] - Christopher R Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe Barter, Karen Rowland-Yeo, Mark Stroh, Eseng Lai, Deborah A Nicoll-Griffith. Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2013 Dec; 43(12):1027-36. doi:
10.3109/00498254.2013.791761. [PMID: 23641955] - Y-L Yang, M Hu, M Chang, B Tomlinson. A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients.
Journal of clinical pharmacy and therapeutics.
2013 Dec; 38(6):528-32. doi:
10.1111/jcpt.12096. [PMID: 24020480] - Fabian Chen, Darbie Maccubbin, Lizhen Yan, Waheeda Sirah, Erluo Chen, Christine McCrary Sisk, Michael Davidson, Peder Blomqvist, James M McKenney. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
International journal of cardiology.
2013 Jul; 167(1):225-31. doi:
10.1016/j.ijcard.2011.12.103. [PMID: 22305632] - Anastazia Kei, Evangelos Liberopoulos, Kostantinos Tellis, Manfredi Rizzo, Moses Elisaf, Alexandros Tselepis. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
European journal of clinical investigation.
2013 Jul; 43(7):698-707. doi:
10.1111/eci.12095. [PMID: 23600368] - E Steinhagen-Thiessen, W Dänschel, C Buffleben, W Smolka, D Pittrow, S K Hildemann. Extended-release niacin/laropiprant for lipid management: observational study in clinical practice.
International journal of clinical practice.
2013 Jun; 67(6):527-35. doi:
10.1111/ijcp.12088. [PMID: 23437867] - Ulf Landmesser. The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin.
European heart journal.
2013 May; 34(17):1254-7. doi:
10.1093/eurheartj/eht064. [PMID: 23444398] - Pascale Labrecque, Sébastien J Roy, Louis Fréchette, Christian Iorio-Morin, Maxime A Gallant, Jean-Luc Parent. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.
PloS one.
2013; 8(6):e65767. doi:
10.1371/journal.pone.0065767. [PMID: 23762421] - Wilfried Dänschel, Elisabeth Steinhagen-Thiessen, Claudia Buffleben, David Pittrow, Steven K Hildemann. Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice.
Current medical research and opinion.
2013 Jan; 29(1):33-40. doi:
10.1185/03007995.2012.750602. [PMID: 23157464] - Darbie L Maccubbin, Fabian Chen, Jennifer Weimer Anderson, Waheeda Sirah, Christine McCrary Sisk, Uma Kher, Anders G Olsson, Harold E Bays, Yale B Mitchel. Effectiveness and safety of laropiprant on niacin-induced flushing.
The American journal of cardiology.
2012 Sep; 110(6):817-22. doi:
10.1016/j.amjcard.2012.05.009. [PMID: 22683042] - ". High patient compliance with nicacin/laropiprant in large clinical trial: interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress: drug trends in cardiology.
Cardiovascular journal of Africa.
2012 Sep; 23(8):471. doi:
". [PMID: 23044505] - Harold Bays, Hilde Giezek, James M McKenney, Edward A O'Neill, Andrew M Tershakovec. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Metabolic syndrome and related disorders.
2012 Aug; 10(4):260-6. doi:
10.1089/met.2012.0005. [PMID: 22400810] - Galin V Michailov, Glenn M Davies, Karl J Krobot. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
The European journal of health economics : HEPAC : health economics in prevention and care.
2012 Jun; 13(3):365-74. doi:
10.1007/s10198-011-0309-z. [PMID: 21465286] - Harold E Bays, Arvind Shah, Jianxin Lin, Christine McCrary Sisk, Qian Dong, Darbie Maccubbin. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
2012 Jun; 12(3):197-206. doi:
10.2165/11631530-000000000-00000. [PMID: 22500948] - Rahul Yadav, Michael France, Naveed Younis, Salam Hama, Basil J Ammori, See Kwok, Handrean Soran. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
Expert opinion on pharmacotherapy.
2012 Jun; 13(9):1345-62. doi:
10.1517/14656566.2012.690395. [PMID: 22607011] - Christie Ballantyne, Gilbert Gleim, Nancy Liu, Christine McCrary Sisk, Amy O Johnson-Levonas, Yale Mitchel. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia.
Journal of clinical lipidology.
2012 May; 6(3):235-43. doi:
10.1016/j.jacl.2011.11.004. [PMID: 22658147] - Sonia Philipose, Viktoria Konya, Mirjana Lazarevic, Lisa M Pasterk, Gunther Marsche, Sasa Frank, Bernhard A Peskar, Akos Heinemann, Rufina Schuligoi. Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation.
PloS one.
2012; 7(8):e40222. doi:
10.1371/journal.pone.0040222. [PMID: 22870195] - Blas Gil-Extremera. Lipid disorders in elderly hypertensive patients.
International journal of hypertension.
2012; 2012(?):684515. doi:
10.1155/2012/684515. [PMID: 22254131] - Rahul Yadav, See Kwok, Basil J Ammori, Basil Issa, Handrean Soran. Safety and tolerability of extended-release niacin with laropiprant.
Expert opinion on drug safety.
2012 Jan; 11(1):151-9. doi:
10.1517/14740338.2011.638281. [PMID: 22133050] - Nuria Maicas, Lidia Ibáñez, María José Alcaraz, Amalia Úbeda, María Luisa Ferrándiz. Prostaglandin D2 regulates joint inflammation and destruction in murine collagen-induced arthritis.
Arthritis and rheumatism.
2012 Jan; 64(1):130-40. doi:
10.1002/art.30656. [PMID: 21898357] - B Sjouke, D M Kusters, J J P Kastelein, G K Hovingh. Familial hypercholesterolemia: present and future management.
Current cardiology reports.
2011 Dec; 13(6):527-36. doi:
10.1007/s11886-011-0219-9. [PMID: 21938413] - Peter Sharpe. Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
Annals of clinical biochemistry.
2011 Nov; 48(Pt 6):584-5. doi:
10.1258/acb.2011.011081. [PMID: 21868415] - Andrew G Bostom, Alexandra A Maclean, Darbie Maccubbin, Diane Tipping, Hilde Giezek, William A Hanlon. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes.
Journal of clinical lipidology.
2011 Jul; 5(4):281-7. doi:
10.1016/j.jacl.2011.03.455. [PMID: 21784373] - Matilda Florentin, Evangelos N Liberopoulos, Anastazia Kei, Dimitri P Mikhailidis, Moses S Elisaf. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.
Current vascular pharmacology.
2011 Jul; 9(4):385-400. doi:
10.2174/157016111796197279. [PMID: 21314635] - Arie Markel. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
The Israel Medical Association journal : IMAJ.
2011 Jun; 13(6):368-74. doi:
. [PMID: 21809737] - M John Chapman, Henry N Ginsberg, Pierre Amarenco, Felicita Andreotti, Jan Borén, Alberico L Catapano, Olivier S Descamps, Edward Fisher, Petri T Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Børge G Nordestgaard, Kausik K Ray, Zeljko Reiner, Marja-Riitta Taskinen, Lale Tokgözoglu, Anne Tybjærg-Hansen, Gerald F Watts. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
European heart journal.
2011 Jun; 32(11):1345-61. doi:
10.1093/eurheartj/ehr112. [PMID: 21531743] - Joachim H Ix, Prerna Ganjoo, Diane Tipping, Andrew M Tershakovec, Andrew G Bostom. Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2011 Jun; 57(6):963-5. doi:
10.1053/j.ajkd.2011.03.010. [PMID: 21496982] - Annett Stahn, Markolf Hanefeld. [Multimodal therapy of dyslipidemia].
Clinical research in cardiology supplements.
2011 May; 6(?):10-6. doi:
10.1007/s11789-011-0031-5. [PMID: 22528173] - H Bays, A Shah, Q Dong, C McCrary Sisk, D Maccubbin. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
International journal of clinical practice.
2011 Apr; 65(4):436-45. doi:
10.1111/j.1742-1241.2010.02620.x. [PMID: 21401833] - Ying-Hong Wang, Fang Liu, Julie Ann Mabalot Luk, Ajay Nirula, Amy O Johnson-Levonas, Kenneth C Lasseter, Thomas C Marbury, N Martin Lunde, John A Wagner, Eseng Lai. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
Journal of clinical pharmacology.
2011 Mar; 51(3):406-12. doi:
10.1177/0091270010369240. [PMID: 20484612] - Marcello Arca, Giovanni Pigna. Treating statin-intolerant patients.
Diabetes, metabolic syndrome and obesity : targets and therapy.
2011; 4(?):155-66. doi:
10.2147/dmso.s11244. [PMID: 21779147] - Helen Vosper. Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.
Clinical Medicine Insights. Cardiology.
2011; 5(?):85-101. doi:
10.4137/cmc.s7601. [PMID: 22084607] - Anastazia Kei, Moses Elisaf, Elisavet Moutzouri, Stavroula Tsiara, Evangelos Liberopoulos. Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study.
International journal of hypertension.
2011; 2011(?):830434. doi:
10.4061/2011/830434. [PMID: 21747984] - Krishnaswami Vijayaraghavan. Treatment of dyslipidemia in patients with type 2 diabetes.
Lipids in health and disease.
2010 Dec; 9(?):144. doi:
10.1186/1476-511x-9-144. [PMID: 21172030] - Peter P Toth. Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease.
Current cardiology reports.
2010 Nov; 12(6):481-7. doi:
10.1007/s11886-010-0136-3. [PMID: 20740329] - Harold E Bays, Arvind Shah, Jianxin Lin, Christine McCrary Sisk, John F Paolini, Darbie Maccubbin. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
Journal of clinical lipidology.
2010 Nov; 4(6):515-21. doi:
10.1016/j.jacl.2010.08.020. [PMID: 21122699] - Anders G Olsson. Recent advances in preventing cardiovascular disorders by managing lipid levels.
F1000 medicine reports.
2010 Sep; 2(?):66. doi:
10.3410/m2-66. [PMID: 21173859] - Fang Liu, Laura Vessey, Larissa Wenning, Sandra Connolly, Melissa Buckland, Amy O Johnson-Levonas, Andrew Denker, John A Wagner, Eseng Lai. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
Journal of clinical pharmacology.
2010 Jul; 50(7):823-8. doi:
10.1177/0091270009356571. [PMID: 20197486] - Anders G Olsson. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Expert opinion on pharmacotherapy.
2010 Jul; 11(10):1715-26. doi:
10.1517/14656566.2010.489894. [PMID: 20518616] - S Sanyal, J T Kuvin, R H Karas. Niacin and laropiprant.
Drugs of today (Barcelona, Spain : 1998).
2010 Jun; 46(6):371-8. doi:
10.1358/dot.2010.46.6.1464844. [PMID: 20571606] - S Shah, R Ceska, B Gil-Extremera, J F Paolini, H Giezek, K Vandormael, A Mao, C McCrary Sisk, D Maccubbin. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
International journal of clinical practice.
2010 May; 64(6):727-38. doi:
10.1111/j.1742-1241.2010.02370.x. [PMID: 20518948] - Ayman A Hussein, Stephen J Nicholls. Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.
Therapeutics and clinical risk management.
2010 Apr; 6(?):183-90. doi:
10.2147/tcrm.s7306. [PMID: 20421916] - Darbie Maccubbin, Diane Tipping, Olga Kuznetsova, William A Hanlon, Andrew G Bostom. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
Clinical journal of the American Society of Nephrology : CJASN.
2010 Apr; 5(4):582-9. doi:
10.2215/cjn.07341009. [PMID: 20299362] - James McKenney, Harold Bays, Michael Koren, Christie M Ballantyne, John F Paolini, Yale Mitchel, Abigaile Betteridge, Olga Kuznetsova, Aditi Sapre, Christine McCrary Sisk, Darbie Maccubbin. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
Journal of clinical lipidology.
2010 Mar; 4(2):105-112.e1. doi:
10.1016/j.jacl.2010.02.002. [PMID: 21122637] - Kai-Hang Yiu, Bernard My Cheung, Hung-Fat Tse. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Expert opinion on investigational drugs.
2010 Mar; 19(3):437-49. doi:
10.1517/13543781003623223. [PMID: 20141348] - . Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
Prescrire international.
2010 Feb; 19(105):9-11. doi:
. [PMID: 20455330] - M John Chapman, Wilfried Le Goff, Maryse Guerin, Anatol Kontush. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
European heart journal.
2010 Jan; 31(2):149-64. doi:
10.1093/eurheartj/ehp399. [PMID: 19825813] - Adie Viljoen, Anthony S Wierzbicki. Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.
Drug, healthcare and patient safety.
2010; 2(?):61-71. doi:
10.2147/dhps.s7302. [PMID: 21701618] - E Windler, B-Chr Zyriax, Chr Bamberger, F Rinninger, F-U Beil. Current strategies and recent advances in the therapy of hypercholesterolemia.
Atherosclerosis. Supplements.
2009 Dec; 10(5):1-4. doi:
10.1016/s1567-5688(09)00065-8. [PMID: 20129365] - Brett Lauring, Victor Dishy, Wen-Lin Luo, Omar Laterza, Jaclyn Patterson, Josee Cote, Alice Chao, Patrick Larson, Maria Gutierrez, John A Wagner, Eseng Lai. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.
Journal of clinical pharmacology.
2009 Dec; 49(12):1426-35. doi:
10.1177/0091270009339593. [PMID: 19833861] - Harold E Bays, Christie Ballantyne. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?.
Current opinion in lipidology.
2009 Dec; 20(6):467-76. doi:
10.1097/mol.0b013e3283325083. [PMID: 19779335] - Jules I Schwartz, Fang Liu, Ying-Hong Wang, Barnali Pramanik, Amy O Johnson-Levonas, Maria J Gutierrez, Eseng Lai, John A Wagner. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
American journal of therapeutics.
2009 Nov; 16(6):487-95. doi:
10.1097/mjt.0b013e3181985130. [PMID: 19940609] - Mark Stroh, Larissa Wenning, Wen-Lin Luo, Rajesh Desai, Sheng Bi, Sara Keshavarz, Nicole Lazarus, Norman Martin Lunde, William B Smith, Michael Schwartz, Julie Stone, John Wagner, Eseng Lai, Victor Dishy. Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.
American journal of therapeutics.
2009 Sep; 16(5):379-84. doi:
10.1097/mjt.0b013e318197c59d. [PMID: 19433974] - V S Kamanna, S H Ganji, M L Kashyap. The mechanism and mitigation of niacin-induced flushing.
International journal of clinical practice.
2009 Sep; 63(9):1369-77. doi:
10.1111/j.1742-1241.2009.02099.x. [PMID: 19691622] - Caroline M Perry. Extended-release niacin (nicotinic acid)/laropiprant.
Drugs.
2009 Aug; 69(12):1665-79. doi:
10.2165/11203730-000000000-00000. [PMID: 19678716] - Darbie Maccubbin, Michael J Koren, Michael Davidson, Dov Gavish, Richard C Pasternak, Geraldine Macdonell, Madhuja Mallick, Christine McCrary Sisk, John F Paolini, Yale Mitchel. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
The American journal of cardiology.
2009 Jul; 104(1):74-81. doi:
10.1016/j.amjcard.2009.02.047. [PMID: 19576324] - Jules I Schwartz, Fang Liu, Mark Stroh, Adrianna Gipson, Amy O Johnson-Levonas, Kenneth C Lasseter, Eseng Lai, John A Wagner. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
American journal of therapeutics.
2009 May; 16(3):215-23. doi:
10.1097/mjt.0b013e31818f9c68. [PMID: 19454860] - Debra Kush, Hyo-Soo Kim, Da Yi Hu, Ji Liu, Waheeda Sirah, Aditi Sapre, Christine McCrary Sisk, John F Paolini, Darbie Maccubbin. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.
Journal of clinical lipidology.
2009 May; 3(3):179-86. doi:
10.1016/j.jacl.2009.04.048. [PMID: 21291812] - Victor Dishy, Fang Liu, David L Ebel, George J Atiee, Jane Royalty, Sandra Reilley, John F Paolini, John A Wagner, Eseng Lai. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Journal of clinical pharmacology.
2009 Apr; 49(4):416-22. doi:
10.1177/0091270009332246. [PMID: 19246721] - Harold E Bays, Darbie Maccubbin, Alan G Meehan, Olga Kuznetsova, Yale B Mitchel, John F Paolini. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
Clinical therapeutics.
2009 Jan; 31(1):115-22. doi:
10.1016/j.clinthera.2009.01.010. [PMID: 19243712] - Debra Kush, Da-Yi Hu, Ping Ye, Hyo-Soo Kim, Erluo Chen, Waheeda Sirah, Christine McCrary Sisk, John F Paolini, Darbie Maccubbin. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
Cardiology.
2009; 114(3):192-8. doi:
10.1159/000228585. [PMID: 19602880] - Jennifer G Robinson. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Vascular health and risk management.
2009; 5(1):31-43. doi:
10.2147/vhrm.s3190. [PMID: 19436666] - Klaus G Parhofer. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
Vascular health and risk management.
2009; 5(?):901-8. doi:
10.2147/vhrm.s4502. [PMID: 20016845] - Benjamin J Ansell. A review of trials evaluating nonstatin lipid-lowering therapies.
Current atherosclerosis reports.
2009 Jan; 11(1):64-6. doi:
10.1007/s11883-009-0010-1. [PMID: 19080730] - D Maccubbin, H E Bays, A G Olsson, V Elinoff, A Elis, Y Mitchel, W Sirah, A Betteridge, R Reyes, Q Yu, O Kuznetsova, C McCrary Sisk, R C Pasternak, J F Paolini. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
International journal of clinical practice.
2008 Dec; 62(12):1959-70. doi:
10.1111/j.1742-1241.2008.01938.x. [PMID: 19166443] - John F Paolini, Harold E Bays, Christie M Ballantyne, Michael Davidson, Richard Pasternak, Darbie Maccubbin, Josephine M Norquist, Eseng Lai, M Gerard Waters, Olga Kuznetsova, Christine McCrary Sisk, Yale B Mitchel. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
Cardiology clinics.
2008 Nov; 26(4):547-60. doi:
10.1016/j.ccl.2008.06.007. [PMID: 19031552] - Vaijinath S Kamanna, Anthony Vo, Moti L Kashyap. Nicotinic acid: recent developments.
Current opinion in cardiology.
2008 Jul; 23(4):393-8. doi:
10.1097/hco.0b013e3283021c82. [PMID: 18520725] - John F Paolini, Yale B Mitchel, Robert Reyes, Uma Kher, Eseng Lai, Douglas J Watson, Josephine M Norquist, Alan G Meehan, Harold E Bays, Michael Davidson, Christie M Ballantyne. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
The American journal of cardiology.
2008 Mar; 101(5):625-30. doi:
10.1016/j.amjcard.2007.10.023. [PMID: 18308010] - Andrew S Felts. Molecule of the Month. TREDAPTIVE (nicotinic acid/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides.
Current topics in medicinal chemistry.
2008; 8(14):1310. doi:
10.2174/156802608785849003. [PMID: 18928015] - Anbu Pandian, Anjali Arora, Laurence S Sperling, Bobby V Khan. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Vascular health and risk management.
2008; 4(5):1001-9. doi:
10.2147/vhrm.s3460. [PMID: 19183748] - Bindhu Karanam, Maria Madeira, Scott Bradley, Larissa Wenning, Rajesh Desai, Eric Soli, David Schenk, Allen Jones, Brian Dean, George Doss, Graigory Garrett, Tami Crumley, Ajay Nirula, Eseng Lai. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Jul; 35(7):1196-202. doi:
10.1124/dmd.107.014696. [PMID: 17431030] - Kang Cheng, Tsuei-Ju Wu, Kenneth K Wu, Claudio Sturino, Kathleen Metters, Keith Gottesdiener, Samuel D Wright, Zhaoyin Wang, Gary O'Neill, Eseng Lai, M Gerard Waters. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.
Proceedings of the National Academy of Sciences of the United States of America.
2006 Apr; 103(17):6682-7. doi:
10.1073/pnas.0601574103. [PMID: 16617107]